7/103 sources · 3 publishersUpdated Oct 28, 14:16 UTC
NovaBridge Biosciences appoints Chuck Silberstein as new chief financial officer
NovaBridge Biosciences announced that Chuck Silberstein, M.D., M.B.A., will become its chief financial officer on November 2, succeeding Kyler Lei. Silberstein brings more than 25 years of biotech and finance experience, having served as CFO at GentiBio and Applied Therapeutics and as CEO of FytonBio. The appointment was disclosed in a company press release.
Why it matters
Shares of NovaBridge rose 5.18% to $1.32 in pre‑market trading after the announcement, indicating investor optimism about the new CFO’s experience.
Key facts
- 1Chuck Silberstein will assume the CFO role on November 2, 2026. investing.com
- 2He replaces outgoing CFO Kyler Lei. investing.com
- 3Silberstein has more than 25 years of experience in biotechnology and finance. investing.com
- 4He previously held CFO positions at GentiBio and Applied Therapeutics and was CEO of FytonBio. investing.com
- 5NovaBridge shares rose 5.18% to $1.32 in pre‑market trading after the news. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.